Knees have been the sore spot in Smith & Nephew's recovery story for some time. The orthopaedics unit has lagged the group's wound care and sports medicine franchises, and the company has admitted as much. That makes the latest news from the medical technology group more than a routine product update.

On 22 September 2026, Smith & Nephew (LSE:SN.), a FTSE 100 constituent, said the US Food and Drug Administration had granted 510(k) clearance for its LANDMARK Total Knee System. It also announced the first surgical cases using the implant. The launch is the company's clearest attempt yet to rebuild momentum in a category where it has been losing ground.

A New Knee Arrives, and the First Operations Are Done

The announcement combined two milestones. The 510(k) clearance allows the company to market the device in the United States, the world's largest orthopaedic market. The first procedures were carried out in London, Ontario, in Canada, by Dr Steven MacDonald, Professor of Orthopaedic Surgery at Western University and London Health Sciences Centre. Dr Steven Haas, Chief of the Knee Service at the Hospital for Special Surgery in New York, is also named as one of the surgeon developers.

Smith & Nephew describes LANDMARK as an anatomy-driven implant designed to replicate a healthy knee's shape and natural motion. Its features include a smooth, flat trochlear groove intended to improve how the kneecap tracks, and a fully 3D-printed femoral component that uses the company's CONCELOC technology. The group says the design restores natural front-to-back positioning with less compromise than conventional implants.

Nate Folkert, President of Orthopaedics, said the future of knee replacement is "increasingly personalized", and that surgeons need tools that help them deliver individual care with confidence and efficiency. The company plans a phased commercial launch starting in 2026, with broader availability expected through 2027.

The Numbers Behind the Knee Problem

The context explains why this matters. In its second quarter and first half 2026 results on 4 August, Smith & Nephew reported first-half Revenue of $3,097m, with underlying growth of 2.3%. Second-quarter revenue was $1,597m, up 1.6% on an underlying basis. Knee implants were the weak link: US knee implant revenue fell 7.2% in the quarter and global knee implants declined 4.3% on an underlying basis.

Chief executive Deepak Nath did not dodge the issue. He said orthopaedics "is not where we want it to be, but we expect growth to accelerate." The group trimmed its 2026 revenue growth guidance to about 4%, down from about 6%, while keeping its target of around 8% trading profit growth and free Cash Flow of about $800m.

Profitability held up better than sales. The trading profit Margin rose 60 basis points to 18.3%, and adjusted Earnings Per Share climbed 11.0% to 47.7 cents. The Interim Dividend increased 4.0% to 15.6 cents, and the company is running a $500m share buyback. The results had also flagged a LANDMARK launch for the third quarter, so the September clearance keeps that timetable on track.

Separately, on 8 September the company announced a cash tender offer for up to $250m of its bonds due 2030, as it manages its Debt profile.

Why Robotics and Surgery Centres Are Part of the Pitch

LANDMARK is not being sold as a standalone implant. Smith & Nephew says it is designed to work with CORI, its handheld robotics platform for knee arthroplasty. The system also has a compact footprint aimed at both hospitals and ambulatory surgery centres.

That second point is important. In the US, a growing share of joint replacements is moving out of large hospitals and into outpatient surgery centres, where space, speed and cost matter. A smaller, robotics-compatible system could help Smith & Nephew compete for that Business against larger rivals such as Stryker and Zimmer Biomet, which have strong positions in both implants and surgical robotics.

For the group as a whole, a healthier knee business would support the margin story management has been telling investors. Orthopaedics sits alongside sports medicine and advanced wound management, and if joint replacement sales stay weak, the burden of growth falls more heavily on the other two divisions. Smith & Nephew employs about 17,000 people in around 100 countries, and reported annual sales of $6.2bn in 2025.

Where the Launch Could Stumble

Regulatory clearance is only a starting point. Knee surgeons tend to be loyal to systems they know, and switching implants involves training, new instruments and changes to hospital inventory. A phased launch that stretches through 2027 means any meaningful revenue benefit may take time to show up in the numbers.

Competition is intense. Rivals are also investing in personalised implants, robotics and data-driven planning, and pricing pressure in US orthopaedics is persistent. Hospital procurement groups often negotiate hard on implant prices, which can squeeze margins even when volumes grow.

There is also execution risk around the wider turnaround. Management has already cut its revenue growth guidance for 2026 once. Weaker-than-hoped Demand in orthopaedics, Supply chain problems or slower uptake of CORI could all put pressure on the target of faster growth in the second half. Long-term clinical performance data will also matter, and that can only build up over years.

The Dates That Matter From Here

The first public showcase for LANDMARK is set for the American Association of Hip and Knee Surgeons Annual Meeting in Dallas from 5 to 8 November 2026. That meeting draws many of the surgeons Smith & Nephew needs to win over, so feedback from the event will be an early test of interest.

The group's third quarter trading update, which it usually publishes around the start of November, will show whether the knee decline has continued to ease. Investors will look for signs of improvement in US knee implants and for any change to the roughly 4% revenue growth guidance.

Full-year results early in 2027 should then give the first real picture of how the launch is going and how the wider rollout will be paced.

Conclusion

FDA clearance for LANDMARK gives Smith & Nephew a fresh product in the category that has held back its recovery, and it arrives with robotics and outpatient centres in mind. The first-half figures show why this matters, but they also show how much ground the knee business has to recover. A phased launch, strong competitors and a trimmed revenue outlook mean the benefits are likely to build gradually rather than quickly.